FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044987966> ?p ?o ?g. }

• W3044987966 endingPage "27" @default.
• W3044987966 startingPage "13" @default.
• W3044987966 abstract "Pre-eclampsia (PE) is a systemic maternal syndrome affecting 2-8% of pregnancies worldwide and involving poor placental perfusion and impaired blood supply to the foetus. It manifests after the 20th week of pregnancy as new-onset hypertension and substantial proteinuria and is responsible for severe maternal and newborn morbidity and mortality. Identifying biomarkers that predict PE onset prior to its establishment would critically help treatment and attenuate outcome severity. MicroRNAs are ubiquitous gene expression modulators found in blood and tissues. Trophoblast cell surface antigen (Trop)-2 promotes cell growth and is involved in several cancers. We assessed the PE predictive ability of maternal miR-125b in the first trimester of pregnancy by measuring its plasma levels in women with normal pregnancies and with pregnancies complicated by PE on the 12th week of gestation. To gain insight into PE pathogenesis we investigated whether Trop-2 is targeted by miR-125b in placental tissue. Data analysis demonstrated a significant association between plasma miR-125b levels and PE, which together with maternal body mass index before pregnancy provided a predictive model with an area under the curve of 0.85 (95% confidence interval, 0.70-1.00). We also found that Trop-2 is a target of miR-125b in placental cells; its localization in the basal part of the syncytiotrophoblast plasma membrane suggests a role for it in the early onset of PE. Altogether, maternal miR-125b proved a promising early biomarker of PE, suggesting that it may be involved in placental development through its action on Trop-2 well before the clinical manifestations of PE. Pre-eclampsia (PE) is a systemic maternal syndrome affecting 2-8% of pregnancies worldwide and involving poor placental perfusion and impaired blood supply to the foetus. It manifests after the 20th week of pregnancy as new-onset hypertension and substantial proteinuria and is responsible for severe maternal and newborn morbidity and mortality. Identifying biomarkers that predict PE onset prior to its establishment would critically help treatment and attenuate outcome severity. MicroRNAs are ubiquitous gene expression modulators found in blood and tissues. Trophoblast cell surface antigen (Trop)-2 promotes cell growth and is involved in several cancers. We assessed the PE predictive ability of maternal miR-125b in the first trimester of pregnancy by measuring its plasma levels in women with normal pregnancies and with pregnancies complicated by PE on the 12th week of gestation. To gain insight into PE pathogenesis we investigated whether Trop-2 is targeted by miR-125b in placental tissue. Data analysis demonstrated a significant association between plasma miR-125b levels and PE, which together with maternal body mass index before pregnancy provided a predictive model with an area under the curve of 0.85 (95% confidence interval, 0.70-1.00). We also found that Trop-2 is a target of miR-125b in placental cells; its localization in the basal part of the syncytiotrophoblast plasma membrane suggests a role for it in the early onset of PE. Altogether, maternal miR-125b proved a promising early biomarker of PE, suggesting that it may be involved in placental development through its action on Trop-2 well before the clinical manifestations of PE." @default.
• W3044987966 created "2020-07-29" @default.
• W3044987966 creator A5001162407 @default.
• W3044987966 creator A5007017193 @default.
• W3044987966 creator A5007174030 @default.
• W3044987966 creator A5013854077 @default.
• W3044987966 creator A5019528189 @default.
• W3044987966 creator A5021394745 @default.
• W3044987966 creator A5026048739 @default.
• W3044987966 creator A5028028388 @default.
• W3044987966 creator A5030668942 @default.
• W3044987966 creator A5034868653 @default.
• W3044987966 creator A5041972948 @default.
• W3044987966 creator A5046705570 @default.
• W3044987966 creator A5054868676 @default.
• W3044987966 creator A5063792008 @default.
• W3044987966 creator A5065818477 @default.
• W3044987966 creator A5068476080 @default.
• W3044987966 creator A5076976885 @default.
• W3044987966 creator A5085026650 @default.
• W3044987966 creator A5088191739 @default.
• W3044987966 creator A5090079532 @default.
• W3044987966 date "2021-02-01" @default.
• W3044987966 modified "2023-10-18" @default.
• W3044987966 title "Pre-eclampsia predictive ability of maternal miR-125b: a clinical and experimental study" @default.
• W3044987966 cites W1536661698 @default.
• W3044987966 cites W1543107147 @default.
• W3044987966 cites W1635741485 @default.
• W3044987966 cites W181487094 @default.
• W3044987966 cites W1885628210 @default.
• W3044987966 cites W1968102833 @default.
• W3044987966 cites W1974320281 @default.
• W3044987966 cites W1977814972 @default.
• W3044987966 cites W1978380229 @default.
• W3044987966 cites W1984970610 @default.
• W3044987966 cites W1993127658 @default.
• W3044987966 cites W1993474041 @default.
• W3044987966 cites W2006920657 @default.
• W3044987966 cites W2010747774 @default.
• W3044987966 cites W2023918126 @default.
• W3044987966 cites W2041049932 @default.
• W3044987966 cites W2042871312 @default.
• W3044987966 cites W2043144595 @default.
• W3044987966 cites W2045306661 @default.
• W3044987966 cites W2047440365 @default.
• W3044987966 cites W2048859550 @default.
• W3044987966 cites W2067720485 @default.
• W3044987966 cites W2077311976 @default.
• W3044987966 cites W2081064968 @default.
• W3044987966 cites W2086091484 @default.
• W3044987966 cites W2086180502 @default.
• W3044987966 cites W2091804814 @default.
• W3044987966 cites W2092279987 @default.
• W3044987966 cites W2094898845 @default.
• W3044987966 cites W2095432971 @default.
• W3044987966 cites W2104134360 @default.
• W3044987966 cites W2108804853 @default.
• W3044987966 cites W2108908642 @default.
• W3044987966 cites W2128949071 @default.
• W3044987966 cites W2130438172 @default.
• W3044987966 cites W2134055438 @default.
• W3044987966 cites W2137433871 @default.
• W3044987966 cites W2142516973 @default.
• W3044987966 cites W2152401910 @default.
• W3044987966 cites W2155028837 @default.
• W3044987966 cites W2156523290 @default.
• W3044987966 cites W2162179983 @default.
• W3044987966 cites W2166845840 @default.
• W3044987966 cites W2167412615 @default.
• W3044987966 cites W2169006947 @default.
• W3044987966 cites W2171641698 @default.
• W3044987966 cites W2171945997 @default.
• W3044987966 cites W2300691429 @default.
• W3044987966 cites W2514898011 @default.
• W3044987966 cites W2551039733 @default.
• W3044987966 cites W2564634123 @default.
• W3044987966 cites W2586411032 @default.
• W3044987966 cites W2587092965 @default.
• W3044987966 cites W2593895983 @default.
• W3044987966 cites W2595667191 @default.
• W3044987966 cites W2609278126 @default.
• W3044987966 cites W2619973233 @default.
• W3044987966 cites W2735313331 @default.
• W3044987966 cites W2736085477 @default.
• W3044987966 cites W2740549244 @default.
• W3044987966 cites W2767353242 @default.
• W3044987966 cites W2767859123 @default.
• W3044987966 cites W2769585013 @default.
• W3044987966 cites W2770175338 @default.
• W3044987966 cites W2774655039 @default.
• W3044987966 cites W2793903717 @default.
• W3044987966 cites W2946525881 @default.
• W3044987966 cites W2967691037 @default.
• W3044987966 cites W2971055500 @default.
• W3044987966 cites W4211054086 @default.
• W3044987966 doi "https://doi.org/10.1016/j.trsl.2020.07.011" @default.
• W3044987966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32726711" @default.
• W3044987966 hasPublicationYear "2021" @default.

• next